Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, Kirito K, Yonemura Y, Mori S, Usuki K, Iwato K, Hashino S, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: tomiyama y. Int J Hematol. 2011 Jul;94(1):71-80. doi: 10.1007/s12185-011-0886-8. Epub 2011 Jun 25. Int J Hematol. 2011. PMID: 21706145 Clinical Trial.
Treatment of primary autoimmune thrombocytopenia (AITP) [1].
Schipperus MR, Fijnheer R, Pabinger I, Godeau B, Michel M, Tomiyama Y, Imbach P, Cuker A, Cines B, Panzer S, Reesink HW. Schipperus MR, et al. Among authors: tomiyama y. Vox Sang. 2012 Apr;102(3):261-8. doi: 10.1111/j.1423-0410.2011.1552.x. Epub 2011 Nov 4. Vox Sang. 2012. PMID: 22050204 No abstract available.
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).
Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Iwato K, Okamoto S, Kurokawa M, Kirito K, Hashino S, Ninomiya H, Mori S, Yonemura Y, Usuki K, Wei H, Lizambri R. Shirasugi Y, et al. Among authors: tomiyama y. Int J Hematol. 2012 Jun;95(6):652-9. doi: 10.1007/s12185-012-1065-2. Epub 2012 Apr 25. Int J Hematol. 2012. PMID: 22532046 Clinical Trial.
Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study.
Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, Ninomiya H, Kosugi H, Ishii K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. Katsutani S, et al. Among authors: tomiyama y. Int J Hematol. 2013 Sep;98(3):323-30. doi: 10.1007/s12185-013-1401-1. Epub 2013 Jul 30. Int J Hematol. 2013. PMID: 23896965 Clinical Trial.
434 results